Literature DB >> 12100231

What should we measure in the diabetic patient and how does this respond to therapy?

Desmond G Johnston1, Stephen Robinson, Shareen Forbes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12100231      PMCID： PMC1874395          DOI： 10.1046/j.1365-2125.2002.01624.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  31 in total

Review 1.  Diabetic nephropathy: pathogenesis, diagnosis, and prevention of progression.

Authors:  R O Estacio; R W Schrier
Journal:  Adv Intern Med       Date:  2001

2.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

3.  Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes.

Authors:  M M Gabir; R L Hanson; D Dabelea; G Imperatore; J Roumain; P H Bennett; W C Knowler
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

4.  LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.

Authors:  B V Howard; D C Robbins; M L Sievers; E T Lee; D Rhoades; R B Devereux; L D Cowan; R S Gray; T K Welty; O T Go; W J Howard
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-03       Impact factor: 8.311

5.  Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk).

Authors:  K T Khaw; N Wareham; R Luben; S Bingham; S Oakes; A Welch; N Day
Journal:  BMJ       Date:  2001-01-06

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.

Authors:  F M Sacks; A M Tonkin; J Shepherd; E Braunwald; S Cobbe; C M Hawkins; A Keech; C Packard; J Simes; R Byington; C D Furberg
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  A comparison study of blood glucose test strips.

Authors:  R C Worth; K Harrison; J Anderson; D G Johnston; K G Alberti
Journal:  Diabetes Care       Date:  1981 May-Jun       Impact factor: 19.112

10.  Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations.

Authors:  C E Walden; R H Knopp; P W Wahl; K W Beach; E Strandness
Journal:  N Engl J Med       Date:  1984-10-11       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.